Header cover image

Taiwanese (TAIEX) Healthcare Sector Analysis

UpdatedFeb 03, 2023
DataAggregated Company Financials
Companies184
  • 7D5.0%
  • 3M14.8%
  • 1Y15.7%
  • YTD4.2%

In the last week, the Healthcare industry is up 3.9%, with Polaris Group leading the way, up 14%. During this same period, the Enimmune underperformed, falling 8.4%. In the last 12 months, the industry was up 14%. Looking forward, earnings are forecast to grow by 60% annually.

Sector Valuation and Performance

Has the Taiwanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Feb 2023NT$1.4tNT$214.5bNT$13.8b21x99.1x6.4x
Sun, 01 Jan 2023NT$1.3tNT$214.5bNT$13.8b20.3x95.2x6.1x
Tue, 29 Nov 2022NT$1.3tNT$214.5bNT$14.1b17.5x91.1x6x
Thu, 27 Oct 2022NT$1.1tNT$207.4bNT$10.8b18x99.1x5.2x
Sat, 24 Sep 2022NT$1.4tNT$207.4bNT$10.8b20.9x128.2x6.6x
Mon, 22 Aug 2022NT$1.3tNT$208.5bNT$12.4b20.4x106.9x6.3x
Wed, 20 Jul 2022NT$1.2tNT$199.0bNT$9.8b21.8x121.1x5.9x
Fri, 17 Jun 2022NT$1.2tNT$199.0bNT$9.8b22.5x123.5x6.1x
Sun, 15 May 2022NT$1.2tNT$206.0bNT$11.5b21.1x102.8x5.7x
Tue, 12 Apr 2022NT$1.3tNT$204.4bNT$12.1b23.4x106.3x6.3x
Thu, 10 Mar 2022NT$1.2tNT$202.1bNT$14.0b23x84x5.8x
Sat, 05 Feb 2022NT$1.1tNT$202.1bNT$14.1b21.8x79.9x5.6x
Mon, 03 Jan 2022NT$1.2tNT$202.1bNT$14.1b21.9x83.1x5.8x
Wed, 01 Dec 2021NT$1.1tNT$202.1bNT$14.1b20.9x78.6x5.5x
Fri, 29 Oct 2021NT$1.0tNT$197.6bNT$13.9b21.2x72.8x5.1x
Sun, 26 Sep 2021NT$1.1tNT$197.1bNT$14.2b21.6x75.2x5.4x
Tue, 24 Aug 2021NT$1.0tNT$197.0bNT$14.1b21.5x72.1x5.2x
Wed, 30 Jun 2021NT$1.1tNT$197.0bNT$14.2b23x78x5.6x
Sat, 03 Apr 2021NT$1.1tNT$191.4bNT$14.8b21.5x72x5.6x
Tue, 05 Jan 2021NT$897.1bNT$185.0bNT$9.5b19.5x94.6x4.9x
Fri, 09 Oct 2020NT$917.4bNT$178.1bNT$4.6b21.6x201x5.2x
Thu, 02 Jul 2020NT$935.2bNT$172.5bNT$1.7b23.9x538.1x5.4x
Sun, 05 Apr 2020NT$519.8bNT$171.3b-NT$2,449,886,500.0018.9x-212.2x3x
Price to Earnings Ratio

-233.9x


Total Market Cap: NT$632.4bTotal Earnings: -NT$2,703,537,000.00Total Revenue: NT$170.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Healthcare Sector Price to Earnings3Y Average 96x202120222023
Current Industry PE
  • Investors are relatively neutral on the Taiwanese Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 96.0x.
  • The 3-year average PS ratio of 5.4x is lower than the industry's current PS ratio of 6.3x.
Past Earnings Growth
  • Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 7.9% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare sector?

TW Market4.55%
Healthcare4.99%
Life Sciences10.47%
Healthtech8.57%
Biotech6.13%
Pharma3.94%
Healthcare Services3.85%
Medical Equipment3.62%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 6.8x.
    • Analysts are expecting annual earnings growth of 119.4%, which is higher than its past year's earnings growth of 19.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 119% over the next 5 years.
  • This is better than its past earnings growth rate of 19% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6446 PharmaEssentiaNT$514.007.9%
+NT$11.3b
77.9%PS64x
6550 Polaris GroupNT$102.5013.9%
+NT$9.3b
46.0%PS6891.7x
4743 Oneness BiotechNT$263.507.8%
+NT$8.0b
10.3%PE90.9x
6586 CHO PharmaNT$137.0014.2%
+NT$3.1b
-8.1%PS7060x
6589 EirGenixNT$119.009.2%
+NT$3.0b
18.4%PS24.4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

4142

NT$40.75

Adimmune

7D

15.6%

1Y

2.9%

4743

NT$263.50

Oneness Biotech

7D

7.8%

1Y

10.3%

6550

NT$102.50

Polaris Group

7D

13.9%

1Y

46.0%

4114

NT$43.40

Synmosa Biopharma

7D

-3.1%

1Y

105.1%

6446

NT$514.00

PharmaEssentia

7D

7.9%

1Y

77.9%

4107

NT$111.00

Bioteque

7D

-1.8%

1Y

-3.5%

6589

NT$119.00

EirGenix

7D

9.2%

1Y

18.4%

6564

NT$58.70

Enimmune

7D

-3.8%

1Y

40.6%

6620

NT$139.00

Handa Pharmaceuticals

7D

17.8%

1Y

163.3%

6586

NT$137.00

CHO Pharma

7D

14.2%

1Y

-8.1%

1799

NT$14.80

Easywell Biomedicals

7D

-6.9%

1Y

-33.6%

6762

NT$224.50

Delta Asia International

7D

-2.4%

1Y

n/a

6847

NT$124.50

Puriblood Medical

7D

-7.1%

1Y

-21.2%

6634

NT$100.50

Sinew Pharma

7D

-2.0%

1Y

18.2%